The Longevity Trade Is No Longer a Buzzword — It’s a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
Source ↗
👁 0
💬 0
From stem cell therapies for frailty to α-Klotho protein programs and GLP-1 drug classes now labeled “longevity therapeutics,” the science and the capital have finally met
Issued on behalf of Avaí Bio, Inc.
Companies mentioned in this commentary include: Avaí Bio, Inc. (OTCQB: AVAI), Eli Lilly and Company (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), Viking Therapeutics, Inc. (NASDAQ: VKTX), Longeveron Inc. (NASDAQ: LGVN).
Key Takeaways:
The global anti-aging market generated more than
Issued on behalf of Avaí Bio, Inc.
Companies mentioned in this commentary include: Avaí Bio, Inc. (OTCQB: AVAI), Eli Lilly and Company (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), Viking Therapeutics, Inc. (NASDAQ: VKTX), Longeveron Inc. (NASDAQ: LGVN).
Key Takeaways:
The global anti-aging market generated more than
Comments (0)